Opposite transcriptional regulation of integrated vs unintegrated HIV genomes by the NF-κB pathway

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Thierry, Sylvain ^a,b   Thierry, Eloïse ^a,c   Subra, Frédéric ^a   Deprez, Eric ^a   Leh, Hervé ^a   Bury Moné, Stéphanie ^a   Delelis, Olivier ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEIC ACID; PROTEIN BINDING; TRANSCRIPTION FACTOR; VIRUS DNA; VIRUS RNA;

CELL LINE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; METABOLISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME;

CELL LINE; DNA, CIRCULAR; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; NF-KAPPA B; NUCLEIC ACIDS; PROTEIN BINDING; RNA, VIRAL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; VIRUS INTEGRATION;

EID: 84968799957     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25678     Document Type: Article

References (54)

1. Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P. & Stevenson, M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254, 423-427 (1991).
2. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 94, 13193-13197 (1997).
3. Butler, S. L., Johnson, E. P. & Bushman, F. D. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. Journal of virology 76, 3739-3747 (2002).
4. Munir, S., Thierry, S., Subra, F., Deprez, E. & Delelis, O. Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle. Retrovirology 10, 87, doi: 10.1186/1742-4690-10-87 (2013).
5. Brussel, A. & Sonigo, P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. Journal of virology 77, 10119-10124 (2003).
6. Sharkey, M. E. et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6, 76-81, doi: 10.1038/71569 (2000).
7. Gillim-Ross, L., Cara, A. & Klotman, M. E. Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. J Gen Virol 86, 765-771, doi: 10.1099/vir.0.80570-0 (2005).
8. Kelly, J. et al. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 372, 300-312, doi: 10.1016/j.virol.2007.11.007 (2008).
9. Pace, M. J., Graf, E. H. & O'Doherty, U. HIV 2-long terminal repeat circular DNA is stable in primary CD4+ T Cells. Virology 441, 18-21, doi: 10.1016/j.virol.2013.02.028 (2013).
10. Graf, E. H. et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLos Pathog 7, e1001300, doi: 10.1371/journal.ppat.1001300 (2011).
11. Buzon, M. J. et al. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. Journal of virology 85, 9646-9650, doi: 10.1128/JVI.05327-11 (2011).
12. Cara, A., Cereseto, A., Lori, F. & Reitz, M. S., Jr. HIV-1 protein expression from synthetic circles of DNA mimicking the extrachromosomal forms of viral DNA. The Journal of biological chemistry 271, 5393-5397 (1996).
13. Nakajima, N., Lu, R. & Engelman, A. Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines. Journal of virology 75, 7944-7955 (2001).
14. Poon, B., Chang, M. A. & Chen, I. S. Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA. Journal of virology 81, 10515-10523, doi: 10.1128/JVI.00947-07 (2007).
15. Gelderblom, H. C. et al. Viral complementation allows HIV-1 replication without integration. Retrovirology 5, 60, doi: 10.1186/1742-4690-5-60 (2008).
16. Thierry, S. et al. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration. Retrovirology 12, 24, doi: 10.1186/s12977-015-0153-9 (2015).
17. Kantor, B., Ma, H., Webster-Cyriaque, J., Monahan, P. E. & Kafri, T. Epigenetic activation of unintegrated HIV-1 genomes by gutassociated short chain fatty acids and its implications for HIV infection. Proceedings of the National Academy of Sciences of the United States of America 106, 18786-18791, doi: 10.1073/pnas.0905859106 (2009).
18. Shimura, K., Miyazato, P., Oishi, S., Fujii, N. & Matsuoka, M. Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread. Virology 484, 364-376, doi: 10.1016/j.virol.2015.06.029 (2015).
19. Chan, C. N. et al. HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Retrovirology 13, 1, doi: 10.1186/s12977-015-0234-9 (2016).
20. Sloan, R. D. & Wainberg, M. A. The role of unintegrated DNA in HIV infection. Retrovirology 8, 52, doi: 10.1186/1742-4690-8-52 (2011).
21. Van Lint, C., Bouchat, S. & Marcello, A. HIV-1 transcription and latency: an update. Retrovirology 10, 67, doi: 10.1186/1742-4690-10-67 (2013).
22. Turrini, F. et al. HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter. Retrovirology 12, 104, doi: 10.1186/s12977-015-0230-0 (2015).
23. Colin, L. & Van Lint, C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6, 111, doi: 10.1186/1742-4690-6-111 (2009).
24. Kilareski, E. M., Shah, S., Nonnemacher, M. R. & Wigdahl, B. Regulation of HIV-1 transcription in cells of the monocytemacrophage lineage. Retrovirology 6, 118, doi: 10.1186/1742-4690-6-118 (2009).
25. Franzoso, G. et al. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature 359, 339-342, doi: 10.1038/359339a0 (1992).
26. Zhang, M. Y., Harhaj, E. W., Bell, L., Sun, S. C. & Miller, B. A. Bcl-3 expression and nuclear translocation are induced by granulocytemacrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. Blood 92, 1225-1234 (1998).
27. Dechend, R. et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 18, 3316-3323, doi: 10.1038/sj.onc.1202717 (1999).
28. Asin, S., Bren, G. D., Carmona, E. M., Solan, N. J. & Paya, C. V. NF-kappaB cis-acting motifs of the human immunodeficiency virus (HIV) long terminal repeat regulate HIV transcription in human macrophages. Journal of virology 75, 11408-11416, doi: 10.1128/JVI.75.23.11408-11416.2001 (2001).
29. Pertel, T. et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361-365, doi: 10.1038/nature09976 (2011).
30. Galao, R. P., Le Tortorec, A., Pickering, S., Kueck, T. & Neil, S. J. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaBdependent proinflammatory responses. Cell host & microbe 12, 633-644, doi: 10.1016/j.chom.2012.10.007 (2012).
31. Tokarev, A. et al. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. Journal of virology 87, 2046-2057, doi: 10.1128/JVI.02272-12 (2013).
32. Lascano, J., Uchil, P. D., Mothes, W. & Luban, J. TRIM5 Retroviral Restriction Activity Correlates with the Ability To Induce Innate Immune Signaling. Journal of virology 90, 308-316, doi: 10.1128/JVI.02496-15 (2015).
33. Postler, T. S. & Desrosiers, R. C. The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-kappaB activation through TGF-beta-activated kinase 1. Cell host & microbe 11, 181-193, doi: 10.1016/j.chom.2011.12.005 (2012).
34. Liu, R. et al. HIV-1 Vpr stimulates NF-kappaB and AP-1 signaling by activating TAK1. Retrovirology 11, 45, doi: 10.1186/1742-4690-11-45 (2014).
35. Charneau, P., Alizon, M. & Clavel, F. A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. Journal of virology 66, 2814-2820 (1992).
36. Delelis, O. et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 54, 491-501, doi: 10.1128/AAC.01075-09 (2010).
37. Brussel, A. & Sonigo, P. Evidence for gene expression by unintegrated human immunodeficiency virus type 1 DNA species. Journal of virology 78, 11263-11271, doi: 10.1128/JVI.78.20.11263-11271.2004 (2004).
38. Li, L. et al. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. The EMBO journal 20, 3272-3281, doi: 10.1093/emboj/20.12.3272 (2001).
39. Nabel, G. & Baltimore, D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326, 711-713, doi: 10.1038/326711a0 (1987).
40. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188, doi: 10.1038/387183a0 (1997).
41. Ashe, M. P., Griffin, P., James, W. & Proudfoot, N. J. Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site. Genes Dev 9, 3008-3025 (1995).
42. Verdin, E. & Van Lint, C. Internal transcriptional regulatory elements in HIV-1 and other retroviruses. Cell Mol Biol (Noisy-le-grand) 41, 365-369 (1995).
43. Colin, L. et al. The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for viral replication. Plos one 6, e19084, doi: 10.1371/journal.pone.0019084 (2011).
44. Saito, K., Saito, M., Taniura, N., Okuwa, T. & Ohara, Y. Activation of the PI3K-Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells. Virology 403, 173-180, doi: 10.1016/j.virol.2010.04.018 (2010).
45. Fujioka, S. et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 24, 7806-7819, doi: 10.1128/MCB.24.17.7806-7819.2004 (2004).
46. Jiang, G. et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 28, 1555-1566, doi: 10.1097/QAD.0000000000000289 (2014).
47. Darcis, G. et al. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1 + JQ1 and Ingenol-B + JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog 11, e1005063, doi: 10.1371/journal.ppat.1005063 (2015).
48. Foley, G. E. et al. Continuous Culture of Human Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 18, 522-529 (1965).
49. Grawunder, U., Zimmer, D., Fugmann, S., Schwarz, K. & Lieber, M. R. DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes. Mol Cell 2, 477-484 (1998).
50. Smith, J. et al. Impact of DNA ligase IV on the fidelity of end joining in human cells. Nucleic acids research 31, 2157-2167 (2003).
51. Manic, G. et al. 3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors. Human gene therapy methods 23, 84-97, doi: 10.1089/hgtb.2011.154 (2012).
52. Ory, D. S., Neugeboren, B. A. & Mulligan, R. C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proceedings of the National Academy of Sciences of the United States of America 93, 11400-11406 (1996).
53. Manic, G. et al. Impact of the Ku complex on HIV-1 expression and latency. PloS one 8, e69691, doi: 10.1371/journal.pone.0069691 (2013).
54. Thierry, S. et al. Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. Journal of virology 78, 12198-12206, doi: 10.1128/JVI.78.22.12198-12206.2004 (2004).